MountainSageNaturalHealth.com

By MountainSageNaturalHealth.com Editorial Team

Kratom has been studied in people, but the controlled human research is small, recent and narrow. Most of what circulates online comes from other kinds of evidence: surveys of people who already use kratom, case reports from clinics and poison centers, and lab and animal work. Each answers a different question, and none shows that kratom works as a treatment. NIDA and NCCIH both say kratom has not been shown to be safe and effective for any medical use.

This page is about the studies themselves: what kinds exist, what each can and cannot show, and how to line a study up against a product label. It does not cover how to take kratom, amounts, preparation or product comparisons, it promises no benefit, and it reviews no product. For the plant and its alkaloids, see What is kratom? and Kratom Alkaloids. For the reasons people report using it, see Why Do People Use Kratom?

What Does the Kratom Research Actually Cover?

Kratom comes from the leaves of Mitragyna speciosa, a tree in the coffee family. NCCIH notes that in Southeast Asia people have traditionally chewed the leaves or brewed them as a tea to fight fatigue. That history is real, but it is background, not a clinical result.

Modern research falls into four groups:

• Controlled human studies. Volunteers receive kratom or a placebo under observation. These can begin to separate a kratom effect from expectation.
• Surveys. People who use kratom describe their own use and reasons. NIDA cites a national survey estimate of about 1.7 million U.S. users aged 12 and older in 2021, and notes that estimates of regular use vary.
• Case reports and poison-center data. Clinicians and poison centers describe what happened to particular people.
• Lab and animal research. FDA says most research focuses on two alkaloids, mitragynine and 7-hydroxymitragynine (7-OH), and that there are published animal studies with kratom extracts.

Are There Clinical Trials of Kratom?

Yes, a few. FDA’s kratom page, current as of December 2, 2025, said there were few published reports from well-designed studies in which kratom was given to humans. Several controlled reports have appeared since. A PubMed search for kratom limited to randomized controlled trials returned five records when we checked on October 9, 2026. A count like that is only a rough guide (the placebo-controlled study of purified mitragynine described below is not on that list), but it shows how small the pool is.

Here are the studies we reviewed, with what each can and cannot tell you. We relied on abstracts and registry records, not full texts.

• Pain-tolerance pilot, 2020. Vicknasingam and colleagues ran a randomized, placebo-controlled, double-blind pilot in Malaysia with 26 men who were regular kratom users. During a one-day inpatient stay, they received a kratom decoction and a placebo drink matched for taste and appearance, in random order. The outcome was how long each person could keep a hand in ice water. The authors reported longer tolerance after the kratom drink. The limits: a small, all-male group of long-time users, tested after a short break from use, on a lab task rather than real-world pain. One competing explanation, in our editorial reading, is that regular users after a break may simply feel better when they get kratom again.
• Single-dose study of kratom leaf, 2026. Reissig and colleagues (authors from FDA, the University of Florida and Altasciences) ran a double-blind pilot in 40 adults who use several recreational drugs and have opioid experience. Each person received one dose of placebo or a single-sourced kratom leaf product. No deaths or serious adverse events occurred. Sleepiness, vomiting and nausea were the most common side effects, higher doses narrowed the pupils, and the highest dose raised ratings such as “drug liking.” The authors caution that results may not represent other kratom products. An FDA-sponsored single-ascending-dose kratom study is also registered as NCT06072170.
• Daily-dose leaf powder trial, 2026. Huestis and colleagues randomized 116 healthy volunteers (49 to a branded kratom leaf powder, 67 to placebo), with single-dose and 15-day daily-dose phases and a 23-day follow-up. Participants were nonsmoking adults aged 18 to 55 who had never used kratom or had not used it for at least 12 months. No serious adverse events or deaths were reported, and side effects generally rose as doses rose. The authors concluded the powder was well tolerated at the ranges tested, with no evidence of meaningful abuse potential or withdrawal. The limits: one product, healthy people, about two weeks of daily use. It cannot speak to long-term use, heavy use, extracts or people with health conditions. A separate 2026 report in Drug Testing and Analysis describes abuse-related outcomes from a randomized, placebo-controlled study of dried kratom leaf powder in healthy kratom-naive adults.
• Purified mitragynine, 2025. Prevete and colleagues ran an early, small, safety-focused (“phase 1”) study. Healthy volunteers received single doses of mitragynine itself, not leaf, in two groups of 8 and 7 people. It was placebo-controlled but single-blind, meaning not everyone involved was kept unaware of what was given. Most measures were unchanged and side effects were mild and brief, though the highest dose raised ratings of amnesia and mild psychological distress. An isolated compound in 15 volunteers does not describe a kratom capsule, tea or extract.
• How the body handles the alkaloids, 2024. A study in Molecules measured blood levels of mitragynine and 7-OH after single and repeated doses of encapsulated leaf powder (the field calls this pharmacokinetics). It describes where compounds go in the body, not whether anything helps.
• Under way. NIDA says it supports research on kratom compounds for pain and opioid withdrawal, and points readers to ClinicalTrials.gov. Psychiatric Times reported in August 2026 on an NIH-led phase 1 safety trial of a mitragynine formulation in healthy volunteers, registered as NCT07204171.

The pattern across these studies: healthy or recreational-drug-using volunteers, short windows, one product at a time, and outcomes about safety and the body’s response. None of the studies we reviewed tested kratom as a treatment for a condition in people who have that condition.

How Do I Read a Kratom Study?

NCCIH’s Know the Science guide to journal articles is a good general primer. For kratom specifically, ask these questions in order:

1. Who took part? Healthy volunteers, regular users and people with a condition are three different groups. A result applies, at most, to people like them.
2. What exactly was given? Leaf powder, a brewed decoction and a purified alkaloid are different things. NIDA says effects depend on the formulation, how it is taken, other drugs in the body, medical conditions and prior experience.
3. What was measured, and for how long? A lab task or a rating scale over hours is not the same as symptoms over months.
4. Was there a comparison group? Placebo and blinding reduce wishful thinking. A survey has neither.
5. How big was it? Dozens of people can show a signal but cannot rule out rare problems.
6. What do the authors say about their limits, and who paid? Check the funding and disclosure statements. FDA itself says its study results must be read against the many varied kratom products on the market.

A label-and-safety map for matching a study to a product

Once you know what a study tested, use this map to see whether it says anything about the product in front of you:

• Botanical name and plant part. Look for Mitragyna speciosa and the part used, such as leaf. A leaf-powder trial does not describe an extract.
• Named alkaloids. A figure for mitragynine or 7-OH on a label is the maker’s statement. FDA says 7-OH is a minor constituent of natural leaf, under 2% of total alkaloids, but far more potent at opioid receptors than mitragynine, and it has a separate page on 7-OH products. The 2026 FDA-linked pilot used a leaf with trace 7-OH, so it does not describe a concentrated 7-OH product.
• Product form. NIDA lists capsules, powder, brewed tea and liquid extract. Evidence from one form does not carry to another.
• Interaction questions. NIDA says many people who use kratom also use other drugs, that case reports link combinations to severe adverse effects, and that more research on interactions is needed. Trials in healthy volunteers are not built to answer questions about your medicines.
• Limits of outcome claims. A page or label promising pain, mood, sleep or withdrawal results goes beyond what NIDA, NCCIH and FDA say the evidence supports. FDA says it acts against false or misleading claims about unproven kratom benefits.

For the general skills behind this, see How to Read an Herbal Supplement Label for Safety Information and What Third-Party Testing Can and Cannot Tell You About Botanicals.

What Remains Unknown About Kratom?

These are open research questions, not settled findings:

• Long-term effects. NIDA says there is little evidence on how kratom affects someone over time, and that case reports link long-term use of large amounts to liver problems in a small minority of people, unpredictably.
• Effects in people who are not healthy volunteers. That includes older adults, people with medical conditions and people on prescribed medicines.
• Pregnancy. NIDA reports very little research, plus case reports of opioid-like withdrawal in newborns of women who regularly used kratom.
• Dependence and abuse potential. FDA’s page said a well-designed human abuse-potential study had not been done and that it awarded a grant for one in September 2024. The 2026 reports above are early data, not a final answer.
• Whether kratom has any therapeutic use. NIDA says animal studies suggest properties that may warrant further study, and that researchers have not proven kratom safe or effective for any medical purpose.

What the Evidence Cannot Tell Us

• Surveys cannot show cause. They show what people who use kratom say about it, not that kratom produced the result.
• Case reports show a signal, not a rate. NIDA describes a 2019 poison-center analysis that linked 11 U.S. deaths between 2011 and 2017 to kratom exposure, two of them with kratom alone. FDA says deaths usually involved other drugs, and NIDA says nearly all involved other drugs or contaminants, so kratom’s own contribution is unclear.
• Lab and animal findings are not human results. A compound that acts on a receptor in a dish or a rat has not been shown to help or harm a person.
• A short, small trial cannot rule out rare events. In our reading, trials of dozens or a hundred-odd volunteers over days or weeks are not sized to detect problems that NIDA says occur unpredictably in a small minority.
• Results do not transfer cleanly between products. NIDA and FDA report contamination in some kratom products, including Salmonella and heavy metals, and each study above tested one specific material.
• No study here tells you what is right for you. That depends on your health history, medicines and circumstances.

Appropriate Next Step

If kratom is on your mind, use what you have learned to prepare questions for a pharmacist or qualified health professional rather than to reach a conclusion on your own. Useful questions:

• Does anything I take, including over-the-counter products, supplements and alcohol, raise a concern alongside kratom?
• Do my liver, heart, mental health or pregnancy status change the picture?
• Which of the studies I have read apply to someone like me, and which do not?
• What symptoms should prompt me to call, and who should I call?

Our guide to building an herb and medicine list for a safer pharmacist conversation shows how to get ready. For a possible poisoning or bad reaction, the Poison Help line is 1-800-222-1222, and in an emergency call 911. You can report a bad reaction to FDA through its MedWatch program. If kratom use feels hard to control, NIDA lists the SAMHSA National Helpline at 1-800-662-4357.

Sources and Limits

We reviewed the pages below on October 9, 2026. Rules and research change quickly, so check the originals.

• U.S. Food and Drug Administration, FDA and Kratom (content current as of December 2, 2025).
• National Institute on Drug Abuse, Kratom (modified March 11, 2026).
• National Center for Complementary and Integrative Health, Kratom (last updated April 2022, the oldest source here).
• PubMed and ClinicalTrials.gov records for the studies linked above.

For the trials we read abstracts and registry records, not full texts. Statements about surveys, case reports and poison-center data come from how NIDA and FDA describe them; we did not open the underlying papers or the World Health Organization’s kratom review. This article describes the research in general and does not evaluate any product, seller or person’s situation.

This article is general education and is not medical or legal advice. Talk with a pharmacist or qualified health care provider about your own medicines, conditions and circumstances.

By MountainSageNaturalHealth.com Editorial Team

What Is Kratom? The Short Answer

Kratom is both a plant and a product category. The plant is Mitragyna speciosa, a tropical tree in the coffee family, native to Southeast Asia. On a product label, “kratom” usually means material from that tree’s leaves, sold as powder, capsules, tea-type preparations or liquid extract. People in Southeast Asia have used the leaves for a long time, and that history is real. But history is context, not proof of safety or benefit.

This page explains what the word covers, how U.S. agencies describe kratom’s status, what label terms can and cannot tell you, and where the research runs out. It does not explain how to take kratom and makes no promise about benefits. Affiliate disclosure: For clarity, this page contains affiliate links. The editors may earn a commission if you buy through them. Your price is the same either way.

Is Kratom a Supplement or a Drug?

The answer depends on which question you mean: how kratom is sold, how it is regulated, or whether it is federally controlled.

How it is sold. The National Institute on Drug Abuse (NIDA) notes that kratom products made from the leaves are marketed as herbal supplements.

How it is regulated. The U.S. Food and Drug Administration (FDA) does not accept that framing. On its kratom page, FDA says kratom is not lawfully marketed in the United States as a drug, a dietary supplement, or a food additive in conventional food. FDA says there are no prescription or over-the-counter kratom drug products legally on the market. Its reasoning on supplements is that kratom is a “new dietary ingredient” (one not marketed as a supplement ingredient before 1994, according to the National Center for Complementary and Integrative Health, or NCCIH), and that the available information does not give reasonable assurance it is free of significant or unreasonable risk of illness or injury. FDA has warned consumers not to use kratom because of the risk of serious adverse events.

Whether it is federally controlled. NIDA and NCCIH both say kratom is currently legal and accessible in many areas of the United States, that the Drug Enforcement Administration (DEA) lists it as a “drug of concern,” and that kratom itself is not on the federal schedule of controlled substances. FDA notes that states may have their own regulations or prohibitions, and NIDA says several countries have banned or restricted kratom. Federal, state and local rules differ, so “legal to sell” and “lawful as a supplement” are not the same statement.

The 7-OH exception. 7-hydroxymitragynine, shortened to 7-OH, occurs naturally in the leaf, but FDA calls it a minor constituent, under 2% of the total alkaloid content of natural leaf. Products built around concentrated or synthetic 7-OH are treated as a separate concern. On July 1, 2026, the DEA announced its intent to temporarily place 7-OH above a proposed threshold, plus three related compounds that do not occur naturally in the plant, in Schedule I. According to a Congressional Research Service legal sidebar updated October 6, 2026, the three related compounds were scheduled by final order effective August 26, 2026, while the 7-OH proposal had not been finalized, so 7-OH was not yet a controlled substance. FDA and DEA both say these actions target concentrated and synthetic products, not natural kratom leaf with only trace 7-OH. This area is moving, so check the FDA 7-OH page and DEA announcements for current status.

What Is Mitragyna speciosa?

NCCIH describes kratom as a tree in the coffee family found in Thailand and neighboring countries. Traditionally in Southeast Asia, people have chewed the leaves or made them into a tea used to fight fatigue and improve work productivity. NCCIH adds that kratom has also been used in religious ceremonies and for symptoms such as pain and diarrhea, sometimes as a substitute for opium. NIDA, citing anthropologists, says this use goes back hundreds of years.

The leaves contain many alkaloids, which NIDA describes as bioactive plant compounds that can affect the body. FDA says kratom contains more than 50 of them, and that most research focuses on two: mitragynine and 7-OH. NIDA says mitragynine is found in the leaf and breaks down into 7-OH in the body during digestion. Both activate mu-opioid receptors, which are structures on the surface of nerve cells that opioid drugs also act on. NIDA says the resulting effects only partly resemble those of opioids such as heroin or oxycodone, and that mitragynine appears to act on other brain systems too, including serotonin and dopamine pathways.

People who use kratom have reported both stimulant-like effects (more energy and alertness, a faster heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion), according to NCCIH and NIDA. NIDA says studies have not established that these effects depend on how much is taken or how. In plain terms, the plant’s name alone cannot tell you what a particular product will do.

What Does “Kratom” Mean on a Label?

Because the word covers a plant, a powder, an extract and a marketing vocabulary, a label is worth reading slowly. These are the terms you are most likely to meet, with what each one can and cannot tell you.

• Botanical name. Look for Mitragyna speciosa and the plant part, such as leaf. The Latin name is a more precise identifier than a common name (our editorial view). Either way, it only tells you what the maker says the plant is, not what is in the container.
• Product form. NIDA describes raw plant material in powder or capsule form, brewed leaf tea, and liquid kratom extract. NIDA says effects can depend on the formulation, the way it is taken, other drugs in a person’s system, underlying medical conditions and prior experience, which is part of why they are hard to predict.
• Named alkaloids. A label that names mitragynine or 7-OH, or gives a percentage, is a statement from the maker. None of the agency pages reviewed here says what such a figure means for any person’s experience, so treat it as a claim to ask about rather than a measure you can rely on. FDA treats concentrated 7-OH products as a separate concern from natural leaf.
• “Lab tested” or “third-party tested.” Ask who tested it, what the test measured and which batch it covers. This matters for kratom in particular: FDA has warned the public about kratom products contaminated with Salmonella and concerning levels of heavy metals, and NIDA reports similar contamination findings. Our guide on what third-party testing can and cannot tell you about botanicals explains why a test of contents is not a statement about safety for you.
• Color or “strain” names. Terms such as red, green or white appear in some kratom marketing. None of the agency pages reviewed here defines them or ties them to measured outcomes, so read them as marketing labels.
• Benefit claims. FDA says it takes action against companies that make false or misleading claims about unproven kratom benefits. A label or page that promises results is a reason for more caution.

For the general skills behind all of this, see our guide on how to read an herbal supplement label for safety information.

What the Evidence Cannot Tell Us

Kratom is widely discussed and thinly studied in people. NCCIH says very little research in people has evaluated its health effects, and FDA says there are published animal studies but few reports from well-designed human studies. Here is what that means in practice.

• Much of what is known comes from surveys, case reports, poison-center data and lab or animal work. These can show that something happened to someone, but they cannot show that kratom caused it.
• Competing explanations are common. NIDA says many people who use kratom also use other drugs and take prescribed medicines. FDA says rare deaths associated with kratom usually involved other drugs, so kratom’s contribution is unclear. NIDA says nearly all such cases involved other drugs or contaminants, and that fatal overdose from kratom alone appears extremely rare.
• Safety concerns are real but not fully mapped. FDA warns about liver toxicity, seizures and substance use disorder. NIDA says people have reported mild effects such as nausea, constipation, dizziness and drowsiness, and case reports describe rare but serious effects, including confusion, tremors and seizures, high blood pressure, slow breathing, and liver problems. NIDA says long-term effects are not well understood, and that effects on driving and other tasks that are dangerous when impaired have not been extensively studied.
• Dependence risk is still being sorted out. FDA says some people have developed substance use disorder after kratom use, and that a well-designed human abuse-potential study has not been done (it awarded a grant for one in September 2024). NIDA says the main compounds act on receptors tied to addictive drugs, though researchers have observed that the way they activate them may lower addiction potential compared with opioids. NIDA adds that the standard psychiatric diagnostic manual has no kratom-specific diagnosis, that studies suggest mild to moderate withdrawal symptoms when regular use stops, and that more research is needed.
• Pregnancy is poorly studied. NIDA reports very little research, along with case reports of opioid-like withdrawal in newborns of women who regularly used kratom, and says many such cases likely involved other substances too.
• Findings do not transfer cleanly between products. FDA says results from its own studies will need to be read against the many varied kratom products on the market.
• Reasons for use are reports, not proof. People report using kratom for pain, mood, fatigue, and to manage withdrawal and cravings. NIDA and NCCIH both say kratom has not been shown to be safe and effective for any medical use. NIDA also notes that approved medications exist for withdrawal and cravings tied to opioid use disorder.
• Use estimates are imprecise. NIDA cites a national survey estimate of about 1.7 million people aged 12 and older (0.6%) using kratom in the past year in 2021, and notes that estimates of regular use vary and that the pandemic affected that survey’s data collection.

What to Do Next

This page is meant to help you ask better questions, not to settle a personal decision. These steps do not depend on any product.

1. Write down what you take. List every prescription, over-the-counter medicine, supplement and herb, with exact product names. Our guide to herb and medicine lists for a safer pharmacist conversation shows how to build one.
2. Bring your questions to a pharmacist or clinician. Useful ones: Does anything I take raise a concern alongside kratom? Do my liver, heart or mental health history change the picture? Does pregnancy, breastfeeding, or planning for either, change the answer? What should I watch for, and who should I call?
3. Check the rules where you live. FDA says state health and law enforcement agencies are the best resource on state law.
4. Know where to turn if something goes wrong. For a possible poisoning or bad reaction, the Poison Help line is 1-800-222-1222, and in an emergency call 911. You can report a bad reaction to FDA through its MedWatch program. If kratom use feels hard to control, NIDA lists the SAMHSA National Helpline at 1-800-662-4357.

Sources and Limits

We opened these pages on October 9, 2026. Rules and web pages change, so check the originals for current details.

• U.S. Food and Drug Administration, FDA and Kratom (content current as of December 2, 2025): marketing status, safety warnings, alkaloids, research gaps.
• U.S. Food and Drug Administration, Hiding in Plain Sight: 7-OH Products (content current as of July 13, 2026): DEA and HHS actions on 7-OH.
• National Institute on Drug Abuse, Kratom (modified March 11, 2026): plant and compounds, forms, reported effects, safety, legal status, research limits.
• National Center for Complementary and Integrative Health, Kratom (last updated April 2022): traditional use, reported effects, safety summary. This is the oldest source and may not reflect newer developments.
• Drug Enforcement Administration, DEA To Temporarily Schedule 7-OH and Related Substances to Protect Public Safety (July 1, 2026): notice of intent.
• Congressional Research Service, Temporary Control of 7-Hydroxymitragynine (7-OH) and Related Substances Under the Controlled Substances Act (updated October 6, 2026): status of the 7-OH proposal and the three related compounds.

We did not open the Federal Register notices themselves, the underlying studies the agency pages cite, the survey report behind the 2021 use estimate, the World Health Organization’s kratom review, or FDA’s 7-OH scientific report. Statements about those documents rely on the agency pages that describe them. This article describes the plant, label vocabulary and state of the evidence in general. It does not evaluate any product, seller or person’s situation, and it does not recommend using kratom.

This article is general education and is not medical or legal advice. Talk with a pharmacist or qualified health care provider about your own medicines, conditions and circumstances.

By MountainSageNaturalHealth.com Editorial Team

Direct Answer and Scope

“Kratom alkaloids” most often refers to two compounds: mitragynine, the primary active alkaloid naturally present in kratom leaf, and 7-hydroxymitragynine (7-OH), a related compound that forms from mitragynine during metabolism or processing. They are chemically related but not the same thing, and federal regulators currently treat them very differently. This page explains what each one is and how it behaves at the receptor level — it does not cover dosing, extraction, or product comparisons, and it does not claim either compound is proven safe or effective for any condition.

What Is Mitragynine

Mitragynine is the most well-studied alkaloid found in the leaves of Mitragyna speciosa, the Southeast Asian tree kratom comes from. According to the National Institute on Drug Abuse (NIDA), mitragynine partially activates mu-opioid receptors — the same receptor type opioid medications act on — while also interacting with adrenergic, serotonin, and dopamine receptors.

That spread across multiple receptor types is part of why kratom’s reported effects vary so widely from person to person. NIDA notes that researchers have not established that stimulant-like versus sedative-like effects depend predictably on dose or method of use, despite that being a common claim in kratom marketing.

What Is 7-Hydroxymitragynine (7-OH)

7-OH is not a separate ingredient added to kratom — it’s what mitragynine becomes. NIDA describes 7-OH as a compound that mitragynine breaks down into after it is ingested and metabolized in the body. 7-OH can also form during the drying and processing of the leaf itself, which is why some commercial products are sold with concentrated or isolated 7-OH content rather than relying on the conversion that happens naturally after ingestion.

This distinction is the center of current U.S. regulatory activity. The FDA has stated that its push to restrict 7-OH is aimed at concentrated, isolated 7-OH products — not natural kratom leaf — and the agency has recommended 7-OH be considered for control as a scheduled substance because of its opioid-receptor activity. The FDA has also issued warning letters to companies selling 7-OH-infused drinks, gummies, and powders.

Is Receptor Activity Proof of Benefit

No. Binding to or activating a receptor describes a chemical interaction — it is not, by itself, evidence that a substance is safe, effective, or beneficial for any condition. NIDA states directly that neither kratom nor its related compounds have been proven safe or effective for any medical purpose, and that there are no FDA-approved uses for kratom.

Much of what’s known about mitragynine and 7-OH at the receptor level comes from animal and laboratory studies rather than controlled human clinical trials. That kind of research can identify a compound worth studying further in people; it is a different, earlier type of evidence than a clinical trial result, and the two should not be read as equivalent.

What the Evidence Cannot Tell Us

• Long-term effects are not well understood. NIDA notes that kratom research is relatively new compared to research on more widely used substances, and that case reports — not controlled long-term studies — are the main source of information on extended regular use.
• Product variability complicates everything. Kratom products differ in potency, formulation, and contamination risk, and some have been found to contain heavy metals or harmful bacteria unrelated to the plant itself.
• Addiction and withdrawal risk is still being characterized. Kratom use does not have a specific diagnosis in the DSM-5, but researchers have observed mild-to-moderate withdrawal symptoms in some regular users. Both mitragynine and 7-OH act on receptors associated with addictive potential, though animal studies suggest their addictive potential may differ from one another.
• 7-OH’s respiratory risk profile differs from mitragynine’s. In laboratory models, 7-OH has been shown to cause respiratory depression that can be reversed with naloxone, while mitragynine itself does not appear to produce the same effect at the rate the body converts it to 7-OH.

None of this is a judgment about any individual product. It reflects where federal research agencies say the evidence currently stands, as of their most recent published updates.

Appropriate Next Step

If you’re trying to understand a specific product label — strain name, alkaloid content claims, or 7-OH disclosures — the most reliable path is reading primary regulatory sources directly, since this is an area where federal guidance is actively evolving. The FDA’s 7-OH product page and NIDA’s kratom research topic page are both maintained and updated as new findings and enforcement actions occur.

If you’re weighing kratom use for a specific health reason, that’s a conversation for a licensed healthcare provider who knows your medication list and health history, particularly given the documented drug-interaction and polysubstance-use risks in the research. For general product-category background, our Golden Monk kratom review covers how strain marketing and label transparency vary across vendors — note that piece is a commercial product review, not a clinical resource.

By MountainSageNaturalHealth.com Editorial Team

Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia with a long history as a traditional remedy and work aid. In the United States, kratom is sold as a botanical product, not as an approved drug or dietary supplement — the FDA has determined it isn’t lawfully marketed as a drug product, a dietary supplement, or a food additive, and the agency has told consumers not to use it for medical treatment. That regulatory gap is exactly why “why do people use it anyway?” is worth asking directly: understanding the reasons people report, and where that self-reported picture runs out, is the useful first step before anyone decides what to do with a kratom product.

This isn’t a guide to how to take kratom, how much to take, or which form works best. It’s a plain look at what researchers and regulators have documented about why people say they use it.

What People Report, and What That Does — and Doesn’t — Tell Us

According to the National Institute on Drug Abuse (NIDA), people who use kratom most often report doing so to manage pain, to ease symptoms of anxiety or depression, to help with fatigue, and to manage cravings or withdrawal tied to opioid or other substance use. Most people who use kratom give more than one reason, not a single motivation. The FDA’s public information lines up with this: people self-treat pain, coughing, diarrhea, anxiety, depression, opioid use disorder, and opioid withdrawal with kratom products.

That word — report — matters. Both agencies are describing what people say about their own experience, not confirming that kratom caused the result.

Why Do People Use Kratom for Pain?

Pain is one of the most frequently cited reasons. Researchers point to kratom’s two best-studied compounds, mitragynine and 7-hydroxymitragynine, which act on the same mu-opioid receptors in the brain as opioid medications, with mitragynine also affecting serotonin, dopamine, and norepinephrine activity. That receptor activity is the working theory behind why some people associate kratom with pain relief.

NIDA is direct about the ceiling on that explanation: kratom has not been proven safe or effective for any medical condition, including pain. The receptor science describes a plausible mechanism — it does not confirm a clinical benefit.

Why Is Kratom Used for Energy?

The energy association goes back centuries, to kratom’s traditional use in Southeast Asia by laborers who chewed the leaves to stay alert through the workday. NIDA notes that people today report both stimulant-like effects — increased energy, alertness, a faster heart rate — and, separately, opioid- and sedative-like effects such as relaxation and pain relief. Some of the research literature on kratom use describes smaller amounts being associated with more stimulant-like reports and larger amounts with more sedative-like reports, but NIDA notes plainly that this pattern hasn’t been confirmed by controlled study — it’s an observation from self-reported use, not an established dose-response relationship.

Are Self-Reports the Same as Clinical Evidence?

No. Self-reported reasons come from surveys, online communities, and case reports — people describing their own experience and motivation. That’s useful for understanding behavior and for pointing future research in the right direction, which is how NIDA uses it. It is not the same as a controlled clinical trial measuring an outcome against a placebo.

NIDA states this directly: while research into kratom’s potential therapeutic uses is ongoing, kratom products have not been demonstrated to be safe and effective for any medical condition. The DSM-5 — the reference clinicians use to diagnose substance-related conditions — doesn’t even include a specific kratom-use diagnosis yet, which gives a sense of how early the formal clinical picture is compared to the volume of self-reported use.

What the Evidence Cannot Tell Us Yet

• Effects vary by product and person. NIDA notes that kratom’s effects depend on the amount taken, the product’s potency and formulation, how it’s consumed, other substances in a person’s system, and individual medical history — which makes any single “why it works” explanation hard to generalize.
• Product content isn’t guaranteed. The FDA and NIDA have both documented kratom products contaminated with heavy metals or bacteria such as Salmonella, meaning a reported effect isn’t always attributable to kratom alone.
• Long-term effects remain understudied. NIDA states there’s little evidence on how regular, long-term kratom use affects someone over time, though case reports have linked heavy long-term use to serious liver problems in a small minority of users.
• Serious adverse effects have been documented. The FDA has warned of risks including liver toxicity, seizures, and substance use disorder associated with kratom use. Both agencies note that most kratom-involved deaths occurred alongside other drugs, which makes kratom’s specific contribution difficult to isolate.

None of this settles whether kratom “works” for any individual’s reason for using it. It marks where self-report ends and where verified clinical science hasn’t yet caught up.

Appropriate Next Step

If you’re trying to understand why kratom comes up in conversations about pain, energy, mood, or opioid withdrawal, the honest answer is: because people report using it for those reasons, and researchers are actively studying whether any of that reported experience holds up under clinical scrutiny. It isn’t an approved treatment for any of them.

Anyone weighing kratom against a specific health concern — particularly pain management, a mental health condition, or opioid withdrawal — is better served by having that conversation with a qualified healthcare provider who knows their full medical picture than by relying on a botanical product with an unsettled safety and efficacy record.